ClinicalTrials.gg

Program

fulipiftide

Also written as “BRM421”, “BRM421 Ophthalmic Solution, 0.03%” and “BRM421 Ophthalmic Solution, 0.06%”.

Its studies are mostly in Dry Eye Syndromes · Keratoconjunctivitis Sicca · Keratitis, led by BRIM Biotechnology.

Furthest: phase 3, since Apr 9, 20205 company-led studies, 2 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BRIM Biotechnology52 open or runningphase 3since Apr 9, 2020Feb 23, 2017Nov 2026phase 2 · NCT07078955

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 23, 2017First study: phase 2 study in Dry Eye SyndromesFirst studyNCT03066219 · 157 enrolled · United States
  2. Apr 9, 2020Phase 3 study in Dry Eye SyndromesNCT04343287 · 220 enrolled · United States
  3. Jan 13, 2023Phase 3 study in Dry Eye SyndromesNCT05695781 · 740 enrolled · United States
  4. May 31, 2023Phase 2 study in Neurotrophic KeratitisNCT05927428 · 12 planned · United States
  5. Jul 14, 2025Phase 2 study in Dry Eye SyndromesNCT07078955 · 99 planned · Taiwan

Ahead

  1. Nov 2026Primary completion: phase 2 study in Dry Eye SyndromesNCT07078955

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07078955Dry Eye Syndromes · Taiwan2Not yet recruitingNov 202699
NCT05927428Neurotrophic Keratitis · United States2RecruitingAug 30, 202512
NCT05695781Dry Eye Syndromes · United States3CompletedDec 30, 2023740
NCT04343287Dry Eye Syndromes · United States3CompletedJun 23, 2020220
NCT03066219Dry Eye Syndromes · United States2CompletedMay 20, 2017157

How it is read

Names in the registry

  • “BRM421”, 2 entries
  • “BRM421 Ophthalmic Solution, 0.03%”, 1 entry
  • “BRM421 Ophthalmic Solution, 0.06%”, 1 entry
  • “BRM424 Ophthalmic Solution - Dose1”, 1 entry
  • “BRM424 Ophthalmic Solution - Dose2”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.